A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Part of paid clinical trials in Anaheim, California.

Sponsor
Incyte Corporation
Study ID
NCT03920852
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label maximum use trial to evaluate ruxolitinib safety and blood levels after its topical application twice daily to affected areas (≥ 25% BSA) in adolescent and adult participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

Key Dates

Start date
May 30, 2019
Status verified
Feb 2020
Primary completion
Dec 26, 2019
Completion
Dec 26, 2019

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib cream

Primary Outcome Measure

Number of treatment-emergent adverse events [ Time Frame: Up to 127 days ]

Locations (9)

FacilityCityStateZIPSite coordinators
Orange County Research CenterAnaheimCalifornia92801-
Encino Research CenterEncinoCalifornia91436-
RM Medical Research, INC.MiamiFlorida33174-
San Marcus Research Clinic, Inc.Miami LakesFlorida33014-
Pure Skin Dermatology Aesthetics at Accel ResearchOrlandoFlorida32819-
Metro Boston Clinical PartnersBrightonMassachusetts02135-
Oakland Hills Dermatology PCAuburn HillsMichigan48326-
Clinical Research Institute of Southern Oregon - CrisorMedfordOregon97504-
Clinical Research Partners LLCRichmondVirginia23220-

Find similar trials in Anaheim, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Orange County Research Center· Anaheim, CAEncino Research Center· Encino, CARM Medical Research, INC.· Miami, FLSan Marcus Research Clinic, Inc.· Miami Lakes, FLPure Skin Dermatology Aesthetics at Accel Research· Orlando, FLMetro Boston Clinical Partners· Brighton, MA

Related Studies